Latest Breaking News On - New york heart association - Page 7 : comparemela.com

VYNDAMAX® (tafamidis) PBS-listed for adult patients with wild-type or hereditary transthyretin amyloid cardiomyopathy (ATTR-CM) with New York Heart Association (NYHA) Class I-II heart failure

SYDNEY, May 4, 2024 /PRNewswire/ Pfizer Australia has welcomed the announcement that VYNDAMAX® (tafamidis), which is approved in Australia for adult

Semaglutide Associated With Improved Symptoms in Obesity-Related HFpEF

Semaglutide is associated with significant improvement in HF-related symptoms and reductions in body weight in patients with obesity-related HFpEF.

Semaglutide Associated With Improved Symptoms in Obesity-Related HFpEF

Semaglutide is associated with significant improvement in HF-related symptoms and reductions in body weight in patients with obesity-related HFpEF.

Catheter Ablation for AFib Shows Little to No Benefit in HFpEF, Despite Positive Effect in HFrEF

A meta-analysis of 12 trials suggests catheter ablation for atrial fibrillation reduces heart failure events in HFrEF patients but not in HFpEF.

scPharmaceuticals Announces First Participant Enrolled in Pivotal Pharmacokinetic Study of FUROSCIX Auto-Injector (furosemide 80mg/mL) Injection